Boardroom Media (CFO News)
At CFO (Boardroom Media) we track over 1,000,000 startups and over 5,000,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top Columbia based CFO’ operating in the Therapeutics space. If you think a CFO’ is missing from this list, feel free to contact our editor on [email protected]
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Neil Klompas
Chief Financial Officer & EVP Business Operations of Zymeworks
Mr. Klompas is Zymeworks’ Chief Financial Officer, and brings over 20 years of healthcare and biotechnology experience to Zymeworks’ management team. Additionally, in conjunction with the CEO, he manages Zymeworks’ corporate growth initiatives including corporate alliances, licensing and partnerships. Prior to joining Zymeworks he worked with KPMG LLP in Canada and the US, most recently with KPMG’s Pharmaceuticals, Biotechnology and Medical Device M&A Transaction Services practice in Princeton NJ, where he advised on numerous transactions including mergers, acquisitions, divestitures and strategic alliances. Prior to that, Mr. Klompas worked with KPMG’s Canadian Biotechnology and Pharmaceuticals practice in the fields of assurance, valuations and taxation. Mr. Klompas is a Chartered Accountant and is a member of the institute of CA’s of British Columbia.
Follow Neil Klompas:
About Zymeworks: Zymeworks is a computational biotechnology company focused on optimizing therapeutic antibodies and other protein-based therapeutics.
Dane Saglio
CFO of Helomics
Dane Saglio serves as Chief Financial Officer of Helomics®. Formerly, Mr. Saglio was the CFO of RegeneRx Biopharmaceuticals, Inc; SuperNova Diagnostics; New Generation Biofuels; EntreMed Biopharmaceuticals; and held senior financial positions with Sterling Software, Inc. and Public Communication Associates. Mr. Saglio also has extensive public and private company experience along with a wide range of corporate finance and strategic transactions experience. Dane earned his B.S. in business administration from the University of Maryland and is a licensed CPA (inactive).
Follow Dane Saglio:
About Helomics, RegeneRx: Helomics provides comprehensive tumor profiling utilizing proprietary tissue-based live cell and fixed cell products and services.
Christopher Hopton
Chief Financial Officer of Sirona Biochem
Christopher Hopton is Sirona Biochem’s Chief Financial Officer. He brings 25 years of expertise in financial management and operations. His extensive experience covers areas of financial planning, accounting policy and business process improvement. As a business investment and finance consultant, Mr. Hopton has worked with several public and privately-held companies. Most recently, Mr. Hopton was the Chief Financial Officer of Central Resources Corp., a junior mineral exploration company. Formerly, he held the position of Division Controller at Canadian Airlines where he was responsible for an annual operating budget of $200M. Mr. Hopton was also involved in the restructuring of 360 Networks, a network communications company, which led to a buyout by Bell Canada. Mr. Hopton earned his Bachelor of Business Administration from Simon Fraser University in British Columbia, Canada and received his professional designation as a Certified General Accountant.
Follow Christopher Hopton:
About Sirona Biochem, Ziptrek: Sirona Biochem is a biotechnology company developing diabetes therapeutics, as well as skin depigmenting and anti-aging agents.
Thomas Kordyback
Chief Financial Officer of RepliCel Life Sciences
Tom Kordyback is a Chartered Accountant and a member of the British Columbia Institute of Chartered Accountants with over 25 years of experience in corporate finance and management for emerging growth companies. From 1984 to 1994, he held senior financial positions with Glenayre Electronics Inc. and Telelink Communications Inc. and worked as a consultant to other Vancouver area companies. In 1995, he began working for Creo, now part of Eastman Kodak Company as their Chief Financial Officer. In this role he oversaw private financings totally over $80 million and in 1999 he led the company’s Initial Public Offering on NASDAQ. He remained at Creo until 2000; at which time, the company had over 4000 employees worldwide. In 2004, Mr. Kordyback joined Extreme CCTV Inc., a developer and manufacturer of state-of-the-art surveillance systems listed on the TSX. He worked for them for three years as a director and member of its Audit, Compensation and Merger and Acquisitions Committees. In 2008 the company was sold to Bosch Security Systems, Inc. for CDN $93 million. Mr. Kordyback currently serves as a director of Silver Sun Resources Corp., a public Canadian-based resource company.
Follow Thomas Kordyback:
About RepliCel Life Sciences: RepliCel Life Sciences is a regenerative medicine company using cell therapy products for healing tendinosis, aging, and pattern baldness.
Cameron Nelson
CFO of Mati Therapeutics
Cameron Nelson is the CFO at Mati Therapeutics.
Follow Cameron Nelson:
About Mati Therapeutics: Mati Therapeutics offers a delivery system to deliver drugs to the surface of the eye through the tear film.
Cameron Nelson
CFO of Mati Therapeutics
Cameron Nelson is the CFO at Mati Therapeutics.
Follow Cameron Nelson:
About Mati Therapeutics: Mati Therapeutics offers a delivery system to deliver drugs to the surface of the eye through the tear film.
William Washecka
CFO of Prestwick Pharmaceuticals
William Washecka is the chief financial officer of [Prestwick Pharmaceuticals](https://www.crunchbase.com/organization/prestwick-pharmaceuticals-inc#/entity), a company that develops and markets therapeutic pharmaceutical drugs for chronic central nervous systems diseases. He was previously a senior partner of Ernst & Young.
Follow William Washecka:
About Ernst & Young, Prestwick Pharmaceuticals: Prestwick Pharmaceuticals develops and markets therapeutic pharmaceutical drugs for chronic central nervous systems diseases.
